^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SNS-101
i
Other names: SNS-101, SNS-VISTA, V-set immunoglobulin domain suppressor of T cell activation
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sensei Biotherap
Drug class:
VISTA antagonist
Related drugs:
1m
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. (PubMed, Nat Commun)
In syngeneic tumor models utilizing human VISTA knock-in mice, SNS-101 shows in vivo efficacy when combined with a PD-1 inhibitor, modulates cytokine and chemokine signaling, and alters the tumor microenvironment. In summary, SNS-101, currently in Phase I clinical trials, emerges as a promising therapeutic biologic for a wide range of patients whose cancer is refractory to current immunotherapy regimens.
PK/PD data • Journal • Checkpoint inhibition
|
PD-1 (Programmed cell death 1)
|
SNS-101
4ms
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=169, Recruiting, Sensei Biotherapeutics, Inc. | N=129 --> 169
Enrollment change • Combination therapy • Metastases
|
Libtayo (cemiplimab-rwlc) • SNS-101
12ms
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=129, Recruiting, Sensei Biotherapeutics, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Libtayo (cemiplimab-rwlc) • SNS-101
1year
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=129, Not yet recruiting, Sensei Biotherapeutics, Inc.
New P1/2 trial • Combination therapy • Metastases
|
Libtayo (cemiplimab-rwlc) • SNS-101
Share via
